Tirzepatide reviews: what the trials and users actually report

Last updated 2026-07-30

What do tirzepatide reviews actually say, in plain terms?

Most honest reviews land in the same place: it works better than older weight-loss drugs, the first few weeks are rough on the stomach, and the biggest complaint isn't the drug itself but the cost and supply headaches. That matches the trial data closely, which is unusual for a weight-loss drug. In the SURMOUNT-1 trial (NCT04184622), adults with obesity or overweight (without diabetes) lost an average of 15.0% of body weight on the 5 mg dose, 19.5% on 10 mg, and 20.9% on 15 mg over 72 weeks, compared to 3.1% on placebo ^[1]. That's not a marketing number, it's the primary result published in the New England Journal of Medicine. For type 2 diabetes, the SURPASS program tells a similar story on blood sugar. In SURPASS-2 (NCT03987919), tirzepatide beat semaglutide 1 mg head-to-head on both A1C reduction and weight loss at 40 weeks ^[2]. That head-to-head trial is a big reason clinicians reach for tirzepatide first when GI tolerance allows it. Where reviews diverge from the topline numbers is the individual variability. Some people lose 25%+ of body weight, others plateau around 8-10%, and a small percentage don't respond meaningfully at all. If you want to see what those individual trajectories actually look like month to month, tirzepatide before and after and tirzepatide results timeline break down the realistic pacing rather than the highlight reel.

How much weight do people actually lose, and how fast?

Weight loss is gradual and dose-dependent, not immediate. In SURMOUNT-1, most of the loss happened over the first 9-12 months of dose escalation and maintenance, with the curve flattening but not fully plateauing by week 72 ^[1]. Here's the breakdown from the trial's efficacy analysis: | Dose | Average weight loss at 72 weeks | Placebo comparison |

What side effects do reviewers report most often?

Gastrointestinal side effects dominate every review site, every trial's adverse event table, and pretty much every conversation about this drug. That's not a red flag exactly, it's the expected mechanism: slowing gastric emptying is part of how GLP-1/GIP drugs work. In SURMOUNT-1, the most common adverse events were nausea (up to 31% at the 15 mg dose), diarrhea (up to 23%), constipation (up to 17%), and vomiting (up to 12%) ^[1]. These were mostly "mild to moderate" per the trial report and clustered around dose increases, not steady-state dosing. Discontinuation due to side effects happened in about 6-7% of tirzepatide-treated participants across the SURMOUNT-1 dose groups, versus roughly 2.6% on placebo ^[1]. So most people who start don't quit from side effects, but a meaningful minority do. Less common but more serious signals showed up too: the FDA label for Zepbound and Mounjaro lists acute pancreatitis, gallbladder disease (including cholelithiasis and cholecystitis), and severe gastroparesis-like symptoms as reported risks ^[3][4]. Gallbladder-related events occurred in roughly 1-2% of tirzepatide-treated patients across trials, a rate a bit higher than placebo. Nobody should read this as "rare enough to ignore": if you get severe, persistent abdominal pain, especially radiating to the back, that's an urgent-care conversation, not a wait-and-see one. Injection site reactions, fatigue, and hair thinning also show up in patient reviews and forums more than they show up prominently in the trial's top-line tables, likely because they're common but not medically serious enough to headline.

Who should not take tirzepatide? What does the boxed warning say?

Tirzepatide carries an FDA boxed warning, the agency's strongest label warning, for thyroid C-cell tumors. It is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) ^[3][4]. The FDA's prescribing information states: "Tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors in rats... It is unknown whether Zepbound causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans" ^[3]. That's an honest hedge on the label itself: the tumor signal is from rodent studies, and no human cases have been confirmed in the current safety database, but the warning stays because the animal signal was strong enough that FDA wants it flagged prominently. Beyond the boxed warning, tirzepatide isn't recommended for people with a history of pancreatitis (use with caution and discontinue if suspected), severe gastrointestinal disease, or diabetic retinopathy that's rapidly worsening (more of a semaglutide-specific signal, but GLP-1 class drugs get watched for it broadly). It's not approved for use in pregnancy, and the label recommends stopping it at least 1 month before a planned pregnancy given data in animal studies showing developmental risk ^[3][4]. People with type 1 diabetes weren't studied in the major efficacy trials and shouldn't use it for glycemic control outside of a research or specialist context. If you're on insulin or a sulfonylurea, hypoglycemia risk goes up when tirzepatide is added, and dose adjustments to those other medications are often needed ^[4].

Zepbound vs Mounjaro vs compounded tirzepatide: what's the real difference?

Same active molecule, different regulatory status, different price tags, and meaningfully different quality assurance. This trips people up constantly. Zepbound is the FDA-approved brand for chronic weight management, approved November 2023 ^[3]. Mounjaro is the FDA-approved brand for type 2 diabetes, approved May 2022 ^[4]. Both are made by Eli Lilly, both contain tirzepatide, and the dosing schedules are essentially identical (2.5 mg starting dose, titrating up to a max of 15 mg weekly). Compounded tirzepatide is a different animal. It's produced by compounding pharmacies, not FDA-approved as a finished drug product, and was legally permissible mainly during the FDA-declared tirzepatide shortage under sections of the Federal Food, Drug, and Cosmetic Act that allow compounding of drugs in shortage. The FDA removed tirzepatide from its drug shortage list in December 2024 ^[5], which narrows the legal basis for mass compounding significantly; compounders can still operate under patient-specific prescriptions for individualized needs (like a different strength or removing an allergen) but not simply to undercut brand pricing. Reviews of compounded product vary wildly, and that's the point: without FDA batch testing, potency and purity aren't guaranteed the way they are for Zepbound or Mounjaro. Some patients report doing fine; others report inconsistent effects between vials, and the FDA has published warnings about adverse events tied to compounded semaglutide and tirzepatide products, including dosing errors from unclear labeling ^[6]. This is exactly why working with a provider-reviewed pathway matters more than it sounds like it should. Tirz Rx exists to help readers compare that landscape and points toward fulfillment through pharmacy partners that are reviewed for sourcing practices, rather than leaving people to guess at unfamiliar websites.

How does tirzepatide compare to semaglutide (Ozempic/Wegovy) in reviews and trials?

Tirzepatide tends to outperform semaglutide on both weight loss and A1C reduction in head-to-head data, though semaglutide has a longer track record and more real-world outcome data (including cardiovascular outcomes data that tirzepatide is still catching up on). The SURPASS-2 trial directly compared tirzepatide (5, 10, and 15 mg) to semaglutide 1 mg in people with type 2 diabetes. All three tirzepatide doses produced greater A1C reductions and greater weight loss than semaglutide 1 mg at 40 weeks ^[2]. That's a genuinely rare finding in this drug class, a real head-to-head win, more than a cross-trial comparison. A separate retrospective cohort study published in JAMA Internal Medicine (2022) using electronic health records found tirzepatide users were more likely to achieve 10%+ and 15%+ weight loss than semaglutide users over 3, 6, and 12 months ^[7]. That's observational data, not a randomized trial, so it carries the usual caveats about who gets prescribed what, but it lines up with the SURPASS-2 signal. On the flip side, semaglutide (as Wegovy) has the SELECT cardiovascular outcomes trial showing a 20% reduction in major adverse cardiovascular events in people with cardiovascular disease and overweight/obesity ^[8], a data point tirzepatide doesn't yet have a matching outcomes trial for (dedicated cardiovascular outcomes trials for tirzepatide are ongoing). If cardiovascular risk reduction independent of weight loss is your priority, that's worth discussing directly with a prescriber.

How long does it take to see results, according to reviews and trial data?

Most reviewers report noticing appetite changes within the first 1-2 weeks, even at the low starting dose, well before meaningful weight loss shows up on the scale. That tracks with the drug's mechanism: GIP and GLP-1 receptor activation affects satiety signaling quickly, independent of accumulated weight loss. In SURMOUNT-1, weight loss was already statistically separating from placebo by week 4, and continued through roughly week 60-72 before the curve started to flatten ^[1]. Practically, that means the first month is mostly about tolerating the drug and dose titration, not big scale movement. Most protocols start at 2.5 mg for 4 weeks (a dose too low to expect much weight loss from, it's there for GI tolerance) before increasing to 5 mg and beyond every 4 weeks as tolerated. So a realistic expectation is: modest loss in month one, accelerating loss through months 3-6, and a longer tail of slower loss into months 9-12 for people who go up to the higher doses. If you want the month-by-month expectation instead of guessing, tirzepatide results timeline walks through what's typical at each stage, and tirzepatide first month what to expect is the more tactical, week-by-week version focused on managing side effects early.

What do reviewers say about cost and insurance coverage?

Cost is the single most common complaint in tirzepatide reviews, and it's not close. List price for Zepbound runs around $1,059.87 per month without insurance for the vial formulation, based on Eli Lilly's published list pricing pages, though actual out-of-pocket costs vary enormously by insurance coverage, pharmacy benefit manager formulary status, and whether a manufacturer savings card applies. Many commercial insurance plans still don't cover Zepbound for weight management, or cover it with strict prior authorization requirements (BMI thresholds, documented failed attempts at other interventions, sometimes a requirement to be enrolled in a structured weight-management program). Mounjaro, for diabetes, tends to get better insurance coverage because diabetes treatment is a more established coverage category than obesity treatment, even though many payers still resist obesity drug coverage broadly. Eli Lilly has run direct-to-consumer offerings (via LillyDirect) at reduced cash prices for certain vial doses, which has shifted some of the review conversation from "impossibly expensive" to "expensive but maybe manageable," depending on the month and the specific offer. Prices and offers change often enough that any specific number should be verified directly against Lilly's current pricing page rather than trusted from an older article, including this one. This cost pressure is exactly why compounded product got so much attention over 2023-2024: it was frequently priced well below brand list price. But cheaper isn't automatically better when the tradeoff is inconsistent sourcing oversight, which is the core reason to route through a provider-reviewed pathway rather than an anonymous online seller.

Is tirzepatide worth it, based on real reviews?

For most people who tolerate the GI side effects, the honest answer from both trial data and patient reviews is yes, it's one of the most effective weight-loss and glycemic drugs available, but "worth it" depends heavily on cost, access, and your tolerance for a multi-month commitment. The efficacy case is strong: 20.9% average weight loss at the top dose in SURMOUNT-1 ^[1], superior A1C and weight outcomes versus semaglutide in SURPASS-2 ^[2]. Reviews largely confirm this holds up outside the trial setting, when people can actually access and afford the drug consistently. The friction points are just as real: GI side effects in the first several weeks for a large minority, a genuine (if small) risk profile around gallbladder and pancreatitis, the boxed thyroid tumor warning that rules some people out entirely, and a cost structure that puts consistent access out of reach for a lot of people without strong insurance. For a fuller weigh-up of the tradeoffs beyond side effects and cost, including who tends to regret starting it and who doesn't, see is tirzepatide worth it and tirzepatide pros and cons.

What happens if you stop tirzepatide? Do reviewers report weight regain?

Yes, and this is one of the more consistent findings across both trial extension data and patient reviews: stopping tirzepatide tends to lead to significant weight regain within a year. The SURMOUNT-4 trial (NCT05024032) specifically tested this by randomizing people who'd already lost weight on tirzepatide to either continue the drug or switch to placebo. The group switched to placebo regained an average of 14 percentage points of body weight (going from roughly 20.9% loss back up to about 9.9% net loss) over the following year, while those who continued tirzepatide continued losing modestly ^[9]. That's a direct, randomized answer to "what happens if I stop," not a guess. This mirrors what's seen with semaglutide discontinuation studies and points to a broader reality about this drug class: it manages a chronic condition (obesity or insulin resistance) rather than curing it. The appetite and satiety changes are pharmacological, and they fade when the drug clears your system, generally over several weeks given tirzepatide's roughly 5-day half-life. Reviewers who stopped for cost reasons, insurance denial, or supply interruption report exactly this pattern anecdotally: cravings return, weight creeps back, sometimes within a couple of months. If long-term maintenance is the goal, budgeting and planning for indefinite use (or a deliberate, medically supervised taper with lifestyle scaffolding) matters more than most people expect going in.

What do reviews say about tirzepatide for people without diabetes vs with diabetes?

The core efficacy pattern holds in both groups, but the numbers differ. People without diabetes (studied in SURMOUNT trials) tend to lose a larger percentage of body weight than people with type 2 diabetes (studied in SURPASS trials), a gap seen consistently across the GLP-1/GIP drug class. In SURMOUNT-2 (NCT04657003), which specifically enrolled people with type 2 diabetes and overweight/obesity, average weight loss was 12.8% at 10 mg and 14.7% at 15 mg over 72 weeks ^[10], notably lower than the 19.5% and 20.9% seen in the non-diabetic SURMOUNT-1 population at the same doses ^[1]. The leading explanation isn't that the drug works differently, it's that insulin resistance and longer metabolic dysfunction histories tend to blunt weight-loss response somewhat across GLP-1 drugs generally. A1C improvements in SURMOUNT-2 were still substantial: roughly 2.1% reduction at the 15 mg dose in a population starting with a baseline A1C around 8.1% ^[10]. So even with a somewhat smaller weight-loss percentage, the glycemic benefit for people with diabetes is significant and often the primary clinical goal anyway, with weight loss as a valuable secondary effect.

Frequently asked questions

Do tirzepatide reviews match the clinical trial results?

Largely yes. Patient reviews consistently describe substantial weight loss (often 15-20%+ over 6-12 months) alongside nausea, diarrhea, or constipation early on, which mirrors SURMOUNT-1's reported 15.0-20.9% average weight loss and its adverse event profile showing nausea in up to 31% of participants at the highest dose ^[1].

What is the most common negative review of tirzepatide?

Cost and access issues dominate negative reviews more than side effects do. Insurance denials, prior authorization hurdles, and list prices around $1,059.87 per month without coverage push many people toward stopping or seeking alternatives, even when the drug itself is working.

Is compounded tirzepatide as good as Zepbound or Mounjaro?

It can be chemically similar, but it isn't FDA-approved as a finished product and doesn't carry the same batch testing guarantees. The FDA removed tirzepatide from its shortage list in December 2024, narrowing when compounding is legally appropriate, and has flagged adverse events tied to compounded GLP-1 products with unclear labeling.

How much weight loss is realistic in the first month on tirzepatide?

Modest. Most protocols start at 2.5 mg, a dose meant for tolerance, not major weight loss. Expect a few pounds in month one, with the bulk of loss happening between months 3 and 9 as the dose titrates up toward 10-15 mg weekly.

What are the most common tirzepatide side effects reported in reviews?

Nausea, diarrhea, constipation, and vomiting, matching SURMOUNT-1's adverse event data (nausea up to 31%, diarrhea up to 23%, constipation up to 17% at the 15 mg dose). Most are described as manageable and tend to cluster around dose increases rather than staying constant.

Who should not take tirzepatide?

Anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome, due to the FDA's boxed warning based on thyroid C-cell tumor findings in rodent studies. People with a history of pancreatitis, severe GI disease, or who are pregnant or planning pregnancy should also avoid it or discuss carefully with a prescriber.

Does tirzepatide work better than Ozempic or Wegovy?

In the SURPASS-2 head-to-head trial, all three tested tirzepatide doses beat semaglutide 1 mg on both A1C reduction and weight loss over 40 weeks. Semaglutide has a cardiovascular outcomes trial (SELECT) showing a 20% MACE reduction that tirzepatide doesn't yet have a matching completed outcomes trial for.

What happens if you stop taking tirzepatide?

Weight regain is common and often substantial. In SURMOUNT-4, people switched from tirzepatide to placebo regained an average of 14 percentage points of body weight over the following year, while those who continued the drug kept losing modestly.

Is tirzepatide safe long-term?

Trial data extends to about 72-88 weeks for most endpoints, showing a consistent side-effect profile without new major safety signals over that period. Longer-term data (multi-year) is still accumulating, and the FDA's boxed warning around thyroid tumors is based on animal studies, with no confirmed human cases so far.

How is tirzepatide different from Mounjaro and Zepbound?

Tirzepatide is the active drug molecule. Mounjaro is Eli Lilly's FDA-approved brand for type 2 diabetes (approved 2022); Zepbound is the FDA-approved brand for chronic weight management (approved 2023). Both contain the same tirzepatide molecule at the same dose range.

Why do some people not lose weight on tirzepatide?

Individual response varies. Trial data shows a spread: some participants lose 25%+ of body weight, others plateau around 8-10%, and a small percentage see minimal change. Dose level, adherence, diet quality, and underlying insulin resistance all affect where someone lands on that curve.

Does tirzepatide cause gallbladder problems?

It can. Gallbladder-related events, including cholelithiasis and cholecystitis, occurred in roughly 1-2% of tirzepatide-treated trial participants, somewhat higher than placebo. Rapid weight loss itself is also an independent risk factor for gallstones, so this risk isn't unique to the drug's mechanism.

How much does tirzepatide cost without insurance?

Zepbound's list price runs around $1,059.87 per month for the vial formulation per Eli Lilly's published pricing, though actual costs vary by dose, pharmacy, and available manufacturer savings offers. Prices change periodically, so check Lilly's current pricing page before budgeting.

Sources

1. Jastreboff et al., NEJM, SURMOUNT-1 trial results: Average weight loss of 15.0%, 19.5%, and 20.9% at 5/10/15 mg doses over 72 weeks, plus adverse event rates
2. Frias et al., NEJM, SURPASS-2 trial results: Tirzepatide outperformed semaglutide 1 mg on A1C and weight loss at 40 weeks
3. FDA, Zepbound prescribing information: Boxed warning on thyroid C-cell tumors, contraindications, and approval details for Zepbound
4. FDA, Mounjaro prescribing information: Boxed warning, contraindications, and approval details for Mounjaro
5. FDA, Drug Shortages Database, tirzepatide status: Tirzepatide shortage resolution status affecting compounding legality
6. FDA, Medication Health Fraud and compounding safety alerts: FDA warnings about adverse events and dosing errors tied to compounded GLP-1 products
7. JAMA Internal Medicine, retrospective cohort comparing tirzepatide and semaglutide: Tirzepatide users more likely to achieve 10%+ and 15%+ weight loss than semaglutide users at 3, 6, and 12 months
8. Lincoff et al., NEJM, SELECT trial results: Semaglutide reduced major adverse cardiovascular events by 20% in SELECT trial
9. ClinicalTrials.gov, SURMOUNT-4 trial record: Weight regain after switching from tirzepatide to placebo in SURMOUNT-4
10. Le Roux et al., The Lancet, SURMOUNT-2 trial results: Weight loss and A1C reduction in people with type 2 diabetes in SURMOUNT-2